PM103 is a proprietary, novel intravenous formulation of clopidogrel bisulfate. Clopidogrel is the active ingredient in PLAVIX® (clopidogrel bisulfate), an orally available antiplatelet drug marketed by Bristol-Myers Squibb and sanofi-aventis. PM103 is being developed in collaboration with CyDex Pharmaceuticals, Inc. as an alternative dosage form to oral PLAVIX for use in the acute care setting.

Related Information

Scientific Poster Presentations

Prism and CyDex Pharmaceuticals, Inc. to Collaborate on Development of Captisol®-enabled Clopidogrel